Trials / Recruiting
RecruitingNCT06734871
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Aibin Liang，MD，Ph.D. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Detailed description
This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT1190B cells in patients with B-NHL. It is planned to enroll 6-24 participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR T cells | chimeric antigen receptor T cells |
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2025-10-13
- Completion
- 2026-07-13
- First posted
- 2024-12-16
- Last updated
- 2025-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06734871. Inclusion in this directory is not an endorsement.